Company Executives

Management Team

From the 10-K annual report

Officer	Age	In this role	Joined	Pay	Source
Yaky Yanay Also a director President Director CEO	54	Not stated	Not stated	Not reported
Liat Zalts CFO & Treasurer	42	Not stated	2022	Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 23, 2026

Directors

serving now

Independent

2 of 2

stated in the proxy; 4 not stated

Average tenure

8.6 years

from year joined

CEO also chairs the board

Alexandre Weinstein

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Alexandre Weinstein Board chair	68	2025 1 year	Not stated	None stated	Sofgen Pharma (OTCM: PROCF)	$63,318
Yaky Yanay CEO	54	2015 11 years	Not stated	None stated	None stated	Paid as CEO
Rami Levi	64	2021 5 years	Independent	Compensation Committee Nominating Committee · Chair	None stated	$93,943
Maital Shemesh-Rasmussen	56	2021 5 years	Independent	Nominating Committee	None stated	$93,943
Doron Shorrer	Not stated	Not stated	Not stated	Audit Committee · Chair	None stated	Not stated
Zami Aberman Leaving at the meeting	Not stated	2005 21 years	Not stated	None stated	None stated	$193,148

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Apr 23, 2026

Chutzpah Holdings Ltd. and Plantae Bioscience Ltd.

a company wholly owned by Mr. Weinstein, a director and Chairman of the Board; Plantae, a corporation controlled by Mr. Weinstein

$4.5 million

2025

Sale to the Purchaser of 400,000 ordinary shares and 175,000 preferred seed-1 shares of Kokomodo Ltd. (approximately 79% of its equity) for an aggregate purchase price payable in 976,139 of the Company's Common Shares.

With Pluri Biotech Ltd. Open in proxy

Chutzpah Holdings Ltd. and Plantae Bioscience Ltd.

a company wholly owned by Mr. Weinstein, a director and Chairman of the Board; Plantae, a corporation controlled by Mr. Weinstein

$0.5 million

2025

Transfer to the Purchaser of a convertible loan with a principal aggregate amount of $0.5 million, under the Share Purchase Agreement.

With Pluri Biotech Ltd. Open in proxy

Comments

Company Executives

Management Team

Board of Directors

Related-party transactions